阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALNY 阿尔尼拉姆制药公司

未开盘 11-09 16:00:00 EST

156.61

+0.67

+0.43%

盘后155.70

-0.91-0.58%

19:56 EST

最高158.70	最低152.17	成交量330.33万
今开156.13	昨收155.94	日振幅4.19%
总市值208.96亿	流通市值208.54亿	总股本1.33亿
成交额5.16亿	换手率2.48%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"阿尔尼拉姆制药公司","latestPrice":156.61,"timestamp":1794258000000,"preClose":155.94,"halted":0,"volume":3303347,"hourTrading":{"tag":"盘后","latestPrice":155.7,"preClose":156.61,"latestTime":"19:56 EST","volume":50272,"amount":7874030.7576,"timestamp":1794272168115,"change":-0.91,"changeRate":-0.005811,"amplitude":0.014047},"delay":0,"changeRate":0.004296524304219674,"floatShares":133157589,"shares":133427910,"eps":19.287748,"marketStatus":"未开盘","change":0.67,"latestTime":"11-09 16:00:00 EST","open":156.13,"high":158.6975,"low":152.1705,"amount":515661749.10507,"amplitude":0.041856,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":19.287748,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794301200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":155.94,"preHourTrading":{"tag":"盘前","latestPrice":157,"preClose":155.94,"latestTime":"09:29 EST","volume":1634,"amount":257829.46458,"timestamp":1794234554662,"change":1.06,"changeRate":0.006797,"amplitude":0.01725},"postHourTrading":{"tag":"盘后","latestPrice":155.7,"preClose":156.61,"latestTime":"19:56 EST","volume":50272,"amount":7874030.7576,"timestamp":1794272168115,"change":-0.91,"changeRate":-0.005811,"amplitude":0.014047},"volumeRatio":0.900751,"impliedVol":0.5145,"impliedVolPercentile":0.8207},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"1141019352","title":"异动解读｜阿尔尼拉姆制药公司盘后上涨5.54%，Amvuttra政策担忧缓和带动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1141019352","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141019352?lang=zh_cn&edition=full","pubTime":"2026-11-05 06:17","pubTimestamp":1793830625,"startTime":"0","endTime":"0","summary":"11月5日，阿尔尼拉姆制药公司盘后上涨5.54%，报170.0美元/股，成交额979.55万美元。消息面上，市场围绕核心产品Amvuttra的340B报销政策不确定性与三季度指引偏保守持续交易，在前期连续回调后，政策担忧阶段性缓和，推动股价反弹。公司此前披露三季度营收14.58亿美元，高于市场预期的14.34亿美元，并维持全年净产品收入47亿至51亿美元区间。机构观点显示，Amvuttra当季销售大体符合预期，尽管TTR收入预期偏向指引下沿，但公司基本面仍被认为稳健，前期跌幅或已部分反映利空。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Amvuttra政策担忧缓和，阿尔尼拉姆盘后上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100523382","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨5.23%，Amvuttra政策担忧缓和带动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1100523382","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100523382?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:45","pubTimestamp":1793803549,"startTime":"0","endTime":"0","summary":"11月4日，阿尔尼拉姆制药公司盘中上涨5.23%，报164.64美元/股，成交额5396.44万美元。消息面上，市场仍围绕核心产品Amvuttra的340B报销政策不确定性与三季度指引偏保守展开交易；在前期连续下挫后，机构对公司基本面仍偏积极的表态，推动股价出现修复。不过也有观点认为，Amvuttra销售大体符合预期、基本面依然稳健，股价前期回调或已部分反映利空。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿尔尼拉姆制药反弹，Amvuttra担忧缓和","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133729737","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.03%，Amvuttra面临340B报销政策不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1133729737","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133729737?lang=zh_cn&edition=full","pubTime":"2026-11-02 23:28","pubTimestamp":1793633325,"startTime":"0","endTime":"0","summary":"11月2日，阿尔尼拉姆制药公司盘中下跌5.03%，报156.695美元/股，成交额1.58亿美元。消息面上，市场继续消化公司核心产品Amvuttra面临的340B报销方案调整风险，这被认为可能对医院端用药形成近期压制。最新机构观点指出，潜在的340B报销变化或在2027年影响Amvuttra医院渠道使用；叠加公司三季度更新显示TTR收入预期靠近全年指引下沿，尽管当季营收高于预期，但增长质量与后续放量节奏仍令情绪承压。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿尔尼拉姆盘中下跌，Amvuttra报销政策存变数","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195193578","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.21%，Amvuttra面临340B报销政策不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1195193578","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195193578?lang=zh_cn&edition=full","pubTime":"2026-10-31 03:24","pubTimestamp":1793388273,"startTime":"0","endTime":"0","summary":"10月31日，阿尔尼拉姆制药公司盘中下跌5.21%，报164.93美元/股，成交额7.43亿美元。消息面上，机构最新指出，公司核心产品Amvuttra面临与340B报销方案调整相关的近期风险，叠加三季度更新显示TTR收入预期靠近全年指引下沿，压制市场情绪。最新观点称，潜在的2027年340B报销变化可能对Amvuttra在医院端使用形成阻力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿尔尼拉姆制药盘中下跌，Amvuttra报销政策存隐忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162307122","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌20.83%，三季度营收超预期但全年指引维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1162307122","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162307122?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:33","pubTimestamp":1793280780,"startTime":"0","endTime":"0","summary":"10月29日，阿尔尼拉姆制药公司盘中下跌20.83%，报190.24美元/股，成交额6170.88万美元。消息面上，公司披露第三季度调整后每股收益16.26美元，营收14.58亿美元，高于市场预期的14.34亿美元；但公司维持全年净产品收入指引在47亿至51亿美元不变，未进一步上调。此前公司曾下调全年净产品收入预期，引发股价明显波动；此次虽交出超预期季度数据，但指引未改善，令投资者情绪继续承压。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿尔尼拉姆制药大跌，全年指引未上调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141024665","title":"异动解读｜阿尔尼拉姆制药公司盘前下跌5.34%，三季度营收虽超预期但市场情绪偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1141024665","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141024665?lang=zh_cn&edition=full","pubTime":"2026-10-29 20:11","pubTimestamp":1793275876,"startTime":"0","endTime":"0","summary":"10月29日，阿尔尼拉姆制药公司盘前下跌5.34%，报223.9美元/股，成交额62.05万美元。消息面上，公司披露三季度调整后每股收益16.26美元，销售额14.58亿美元，高于市场预期的14.34亿美元。但公司此前在7月底曾因下调全年净产品收入指引至47亿至51亿美元引发股价大跌，市场对后续增长持续性仍较敏感。阿尔尼拉姆制药公司是一家专注于RNAi疗法研发的生物制药公司，致力于通过基因沉默机制开发针对多种疾病的新型治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿尔尼拉姆盘前下跌，营收超预期仍承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136098574","title":"财报前瞻 | 阿尔尼拉姆制药公司本季度营收预计增47.06%，机构多数看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1136098574","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136098574?lang=zh_cn&edition=full","pubTime":"2026-10-22 10:12","pubTimestamp":1792635162,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司将在2026年10月29日（盘前）发布财报，市场关注盈利动能与价格体系调整对收入与利润的综合影响。一致预期显示，本季度公司营收预计为14.38亿美元，同比增长47.06%；调整后每股收益预计为1.73美元，同比增长131.66%；息税前利润预计为3.09亿美元，同比增长146.64%。近期市场预期本季度营收同比增长47.06%，与之对应的是公司在售产品的放量节奏与价格体系校准之间的动态平衡。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 阿尔尼拉姆制药公司本季度营收预计增47.06%，机构多数看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160306169","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.13%，多家投行下调目标价持续压制情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1160306169","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160306169?lang=zh_cn&edition=full","pubTime":"2026-10-01 23:19","pubTimestamp":1790867977,"startTime":"0","endTime":"0","summary":"10月1日，阿尔尼拉姆制药公司盘中下跌5.13%，报234.09美元/股，成交额1.51亿美元。消息面上，近期多家投行密集调整目标价。摩根大通维持增持评级但将目标价由375美元下调至369美元，Cantor Fitzgerald重申中性评级及325美元目标价。此前RBC已将目标价大幅削减至350美元，美银证券亦从460美元降至410美元。投行连续下修目标价反映市场对公司增长前景趋于审慎。阿尔尼拉姆制药是一家专注于RNA干扰疗法的生物制药公司，核心产品覆盖罕见病及心血管疾病领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"阿尔尼拉姆盘中走低，投行密集下调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192015762","title":"异动解读｜阿尔尼拉姆制药公司盘前下跌5.3%，报252.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192015762","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192015762?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:04","pubTimestamp":1788869099,"startTime":"0","endTime":"0","summary":"9月8日，阿尔尼拉姆制药公司盘前下跌5.3%，报252.0美元/股，成交额84.7万美元。阿尔尼拉姆制药公司所在的生物科技行业中，整体表现偏弱，个股中，Moderna跌1.54%，艾伯维公司跌0.87%，吉利德科学跌1.14%，安进跌6.09%，再生元制药公司跌1.18%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113438056","title":"异动解读｜阿尔尼拉姆制药盘中上涨5.22%，竞品数据失利叠加机构看好下一代管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1113438056","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113438056?lang=zh_cn&edition=full","pubTime":"2026-09-02 23:21","pubTimestamp":1788362480,"startTime":"0","endTime":"0","summary":"9月2日，阿尔尼拉姆制药盘中上涨5.22%，报258.95美元/股，成交额1.86亿美元。消息面上，Oppenheimer近日发布研报指出，Alnylam最新数据增强了其下一代药物Nucresiran及TRITON-CM临床试验成功的前景，并支持股价短期上行空间。与此同时，竞争对手Eplontersen的联合用药数据表现不佳，市场认为这反而凸显了Alnylam在研管线的差异化优势，进一步巩固了投资者对其下一代产品的信心。值得关注的是，公司此前因二季度下调全年收入指引至47亿至51亿美元区间，股价曾大幅回落逾22%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"竞品失利反衬优势，阿尔尼拉姆盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185627863","title":"异动解读｜阿尔尼拉姆制药公司盘前下跌5.65%，报223.2美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185627863","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185627863?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:57","pubTimestamp":1787914648,"startTime":"0","endTime":"0","summary":"8月28日，阿尔尼拉姆制药公司盘前下跌5.65%，报223.2美元/股，成交额25.39万美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，Moderna涨2.16%，艾伯维公司涨0.12%，安进涨0.69%，吉利德科学涨0.56%，Revolution Medicines涨0.7%。阿尔尼拉姆制药公司是一家基于RNA干扰（RNAi）技术的生物制药公司，致力于通过选择性沉默特定基因来开发治疗多种疾病的新型疗法，核心产品Amvuttra用于治疗转甲状腺素蛋白淀粉样变性心肌病。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137315437","title":"异动解读｜阿尔尼拉姆制药公司盘后上涨5.75%，报232.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137315437","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137315437?lang=zh_cn&edition=full","pubTime":"2026-08-21 07:27","pubTimestamp":1787268437,"startTime":"0","endTime":"0","summary":"8月21日，阿尔尼拉姆制药公司盘后上涨5.75%，报232.0美元/股，成交额912.46万美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股表现分化，其中Moderna跌2.41%，艾伯维公司涨0.39%，安进涨0.1%，吉利德科学涨0.11%，福泰制药跌0.42%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143367358","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.07%，报229.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143367358","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143367358?lang=zh_cn&edition=full","pubTime":"2026-08-21 02:53","pubTimestamp":1787252013,"startTime":"0","endTime":"0","summary":"8月21日，阿尔尼拉姆制药公司盘中下跌5.07%，报229.91美元/股，成交额2.48亿美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股表现普遍承压，其中Moderna跌22.66%，安进跌2.08%，吉利德科学跌1.88%，艾伯维公司跌0.90%，Hyperliquid Strategies Inc涨3.41%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153319685","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨5.06%，报239.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153319685","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153319685?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:08","pubTimestamp":1787148490,"startTime":"0","endTime":"0","summary":"8月19日，阿尔尼拉姆制药公司盘中上涨5.06%，报239.35美元/股，成交额3314.27万美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股表现分化明显，其中Moderna涨128.42%，BioNTech涨23.74%，安进涨3.22%，艾伯维公司涨1.98%，Forte BioSciences涨0.06%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186363034","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.04%，Q2指引下调后持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1186363034","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186363034?lang=zh_cn&edition=full","pubTime":"2026-08-07 03:11","pubTimestamp":1786043490,"startTime":"0","endTime":"0","summary":"8月7日，阿尔尼拉姆制药公司盘中下跌5.04%，报217.2美元/股，成交额2.71亿美元。财报公布后股价单日暴跌约28%，此后虽有技术性反弹，但市场对增长斜率放缓的担忧仍在消化中。RBC将目标价从445美元大幅下调至350美元，Stifel下调至318美元，均维持正面评级但承认短期不确定性上升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169468558","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨5.47%，多家机构维持看好评级称此前跌幅过度","url":"https://stock-news.laohu8.com/highlight/detail?id=1169468558","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169468558?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:07","pubTimestamp":1785766037,"startTime":"0","endTime":"0","summary":"8月3日，阿尔尼拉姆制药公司盘中上涨5.47%，报218.375美元/股，成交额1.73亿美元。此前公司因Q2营收不及预期及全年指引下调，股价在7月30日单日暴跌逾28%。Stifel同期维持买入评级，目标价调至318美元。公司Q2调整后每股收益1.84美元超预期18.71%，同比增长475%，管理层重申至2030年总收入复合增速超25%的目标。多家机构集体维持正面评级，缓解了市场恐慌情绪，推动股价技术性反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿尔尼拉姆制药公司盘中上涨5.47%，多家机构维持看好评级称此前跌幅过度","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158920980","title":"异动解读 | 阿尔尼拉姆制药公司盘中大跌27.20%，全年产品收入指引下调叠加营收不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1158920980","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158920980?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:14","pubTimestamp":1785420870,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司今日盘中股价大幅下挫27.20%，引发市场高度关注。更为关键的是，公司将2026年全年产品净收入指引从此前的49亿至53亿美元下调至47亿至51亿美元，这一调整直接触发了市场的恐慌性抛售。此外，美银证券此前已对核心产品Amvuttra的长期净价格侵蚀表达担忧，预计竞争压力将持续至2031年，并将目标价从460美元下调至410美元。营收不及预期与全年指引下调形成共振，进一步验证了市场对竞争格局恶化的担忧，导致股价承受显著抛压。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180271424","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌20.29%，Q2营收不及预期叠加全年指引下调","url":"https://stock-news.laohu8.com/highlight/detail?id=1180271424","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180271424?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:41","pubTimestamp":1785418862,"startTime":"0","endTime":"0","summary":"7月30日，阿尔尼拉姆制药公司盘中下跌20.29%，报218.605美元/股，成交额1.84亿美元。消息面上，公司发布第二季度财报：调整后每股收益1.84美元，同比大幅增长；营收12.91亿美元，低于市场一致预期的13.2亿美元。更为关键的是，公司将全年净产品收入指引由此前的49亿至53亿美元下调至47亿至51亿美元，引发市场对增长放缓的担忧。营收不及预期与指引下调共振，验证了市场对竞争格局恶化的担忧，导致股价承受显著抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175560090","title":"阿尔尼拉姆制药公司公布2026年第二季度财报，并重点回顾近期阶段性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1175560090","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175560090?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:02","pubTimestamp":1785412965,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司于近日正式披露了2026年第二季度的财务业绩。与此同时，该公司还着重梳理了在过去一段时间内所取得的各项关键进展。在回顾近期发展时，阿尔尼拉姆强调，其针对多项罕见病及常见疾病的RNAi疗法研究已进入新的里程碑阶段。总体而言，这段时期标志着阿尔尼拉姆在科学探索与商业价值实现上均迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0889565916.HKD","BK4139","LU0882574055.USD","BK4588","LU0320765992.SGD","LU0109394709.USD","LU0114720955.EUR","ALNY","BK4548","GNMX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193228171","title":"异动解读 | 财报发布日遭遇高预期与竞争担忧，阿尔尼拉姆制药盘前大跌7.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193228171","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193228171?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:02","pubTimestamp":1785412954,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司今日盘前大跌7.45%，报265.28美元/股，成交额43.81万美元，引发市场关注。今日为公司第二季度财报发布日（盘前），市场此前对本季度业绩抱有较高预期。美银证券此前指出，本季度业绩将决定全年收入落在指引区间的何处，以及管理层是否进一步调整指引。此外，美银证券对Amvuttra的长期净价格侵蚀表达担忧，预计竞争压力将持续至2031年，并将目标价从460美元下调至410美元。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.0549},{"period":"1month","weight":-0.3051},{"period":"3month","weight":-0.2886},{"period":"6month","weight":-0.4715},{"period":"1year","weight":-0.646},{"period":"ytd","weight":-0.6078}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。RNAi是一种在生物体内细胞中自然产生的选择性沉默及调控表达的特定基因。由于许多疾病是因为特定基因的不适当活动引起的，通过RNAi对于基因的选择性沉默能力可以为治疗许多人类疾病提供一种新的途径。公司认为，通过RNAi原理工作的药物有潜力成为的一种新的药物分类，诸如小分子药物、蛋白质药物以及抗体药物等。通过已经建立RNAi的知识产权以及专业技术，公司正在开发一套生物化学方法以帮助公司建立一个系统，通过该系统可以研发改进RNAi对于各种疾病的治疗方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002754},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.012836},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.021744},{"month":5,"riseRate":0.590909,"avgChangeRate":0.038262},{"month":6,"riseRate":0.608696,"avgChangeRate":0.061553},{"month":7,"riseRate":0.652174,"avgChangeRate":0.088481},{"month":8,"riseRate":0.608696,"avgChangeRate":0.042836},{"month":9,"riseRate":0.565217,"avgChangeRate":0.034006},{"month":10,"riseRate":0.391304,"avgChangeRate":-0.05459},{"month":11,"riseRate":0.695652,"avgChangeRate":0.072773},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"阿尔尼拉姆制药公司","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔尼拉姆制药公司,ALNY,阿尔尼拉姆制药公司股票,阿尔尼拉姆制药公司股票老虎,阿尔尼拉姆制药公司股票老虎国际,阿尔尼拉姆制药公司行情,阿尔尼拉姆制药公司股票行情,阿尔尼拉姆制药公司股价,阿尔尼拉姆制药公司股市,阿尔尼拉姆制药公司股票价格,阿尔尼拉姆制药公司股票交易,阿尔尼拉姆制药公司股票购买,阿尔尼拉姆制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}